Should Pancreatic Cancer Trial Progress Require Action From Revolution Medicines (RVMD) Investors?

Simply Wall St.10-29 21:40

Revolution Medicines reported new exploratory subgroup data from the Phase 3 RASolute 302 trial and received a positive EMA CHMP opinion for RASONQUE in previously treated metastatic pancreatic cancer...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2679228502?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","is_english":true,"pubTime":"2026-10-29 21:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2679228502","market":"hk","top_or_hot":-1,"title":"Should Pancreatic Cancer Trial Progress Require Action From Revolution Medicines (RVMD) Investors?","media":"Simply Wall St.","content":"<div>\n<p>Revolution Medicines reported new exploratory subgroup data from the Phase 3 RASolute 302 trial and received a positive EMA CHMP opinion for RASONQUE in previously treated metastatic pancreatic cancer...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/should-pancreatic-cancer-trial-progress-require-action-from\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should Pancreatic Cancer Trial Progress Require Action From Revolution Medicines (RVMD) Investors?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould Pancreatic Cancer Trial Progress Require Action From Revolution Medicines (RVMD) Investors?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-29 21:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/should-pancreatic-cancer-trial-progress-require-action-from><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Revolution Medicines reported new exploratory subgroup data from the Phase 3 RASolute 302 trial and received a positive EMA CHMP opinion for RASONQUE in previously treated metastatic pancreatic cancer...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/should-pancreatic-cancer-trial-progress-require-action-from\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BBH","symbol_name":"VanEck Biotech ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/should-pancreatic-cancer-trial-progress-require-action-from","article_id":"2679228502","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/should-pancreatic-cancer-trial-progress-require-action-from","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2679228502","pubTimestamp":1793281217,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Revolution Medicines reported new exploratory subgroup data from the Phase 3 RASolute 302 trial and received a positive EMA CHMP opinion for RASONQUE in previously treated metastatic pancreatic cancer, reinforcing the clinical and regulatory profile of its lead RAS targeted therapy.\nThe breadth of overall survival benefit across RAS genotypes and chemotherapy backbones, combined with a potential first EU approval, directly affects how durable and scalable RASONQUE could be within the broader...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BBH":"VanEck Biotech ETF","ON":"安森美半导体","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1983260115.SGD":"Janus Henderson Horizon Global Sustainable Equity A2 SGD-H","ONG":"Leverage Shares 2X Long ON Daily ETF","IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","BK4605":"半导体精选","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU1861214812.USD":"Blackrock Future of Transport A2 USD","LU0724618433.USD":"BGF NEW ENERGY \"A4\" (USD) INC","IE00BZ199S13.USD":"BNY MELLON MOBILITY INNOVATION \"B\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","BK4585":"ETF&股票定投概念","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1861219969.SGD":"Blackrock Future of Transport A2 SGD-H","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","BK4211":"区域性银行","LU1861215975.USD":"贝莱德新一代科技基金 A2","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","RVMD":"Revolution Medicines, Inc.","LU1548497426.USD":"安联环球人工智能AT Acc","BK4097":"系统软件","ONX":"Tradr 2X Long ON Daily ETF","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","LU0124384867.USD":"贝莱德新能源基金A2","LU1861220033.SGD":"Blackrock Next Generation Technology A2 SGD-H","LU2298322129.HKD":"BGF SUSTAINABLE ENERGY \"A2\" (HKDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4512":"苹果概念","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2360107325.USD":"BGF FUTURE OF TRANSPORT \"A4\" (USD) INC","ISBC":"投资者银行","PTH":"Invesco Dorsey Wright Healthcare Momentum ETF","PRGS":"Progress Software Corporation","LU1978683503.SGD":"Blackrock Sustainable Energy A2 SGD-H","BK4141":"半导体产品","CANC":"TEMA ONCOLOGY ETF","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4139":"生物科技","BK4588":"碎股","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00BD6J9T35.USD":"NEUBERGER BERMAN NEXT GENERATION MOBILITY \"A\" (USD) ACC","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","IDNA":"iShares Genomics Immunology and Healthcare ETF"},"translate_title":"胰腺癌试验进展是否需要 Revolution Medicines (RVMD) 投资者采取行动？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CANC":0.6,"PRGS":1.5,"IDNA":0.6,"ISBC":1.5,"ONG":0.6,"RVMD":1.5,"ONX":0.6,"PTH":0.6,"BBH":0.6,"ON":1},"content_text":"Revolution Medicines reported new exploratory subgroup data from the Phase 3 RASolute 302 trial and received a positive EMA CHMP opinion for RASONQUE in previously treated metastatic pancreatic cancer, reinforcing the clinical and regulatory profile of its lead RAS targeted therapy. The breadth of overall survival benefit across RAS genotypes and chemotherapy backbones, combined with a potential first EU approval, directly affects how durable and scalable RASONQUE could be within the broader RAS(ON) franchise at Revolution Medicines. This section now considers how the investment narrative for Revolution Medicines may evolve as RASolute 302 survival data supports a broader RASONQUE opportunity.  Capture how Revolution Medicines fits into the broader oncology opportunity set by scanning a hand picked group of 36 healthcare AI stocks that are also trying to reshape cancer treatment.\nAdvertisementRevolution Medicines Investment Narrative Recap Owning Revolution Medicines means buying into RAS targeted oncology as a platform, with a heavy near term focus on RASONQUE execution in pancreatic cancer and on turning a late stage pipeline into commercial therapies. The business still reports no revenue and is spending heavily, with 2026 GAAP operating expenses guided to US$1.6b to US$1.7b. The key short term catalyst is how well RASONQUE launch metrics track against those costs. The recent RASolute 302 subgroup data supports that opportunity but does not remove execution risk on pricing, uptake or duration. The biggest risk right now is concentration. Most of the clinical and commercial future depends on RAS(ON) inhibitors performing across several tumor types while the company absorbs rising fixed costs in R&D, headcount and a new sales force. Any slowdown in adoption or weaker data in other Phase 3 trials could leave high cash burn and limited revenue offsets. For a shareholder, the belief has to be that current funding, including US$2.03b in cash and investments and access to Royalty Pharma capital, lasts long enough for multiple indications to reach meaningful uptake before further dilution or expensive financing. The recent CHMP positive opinion for RASONQUE in previously treated metastatic pancreatic cancer in the EU is the most relevant development for this story. It directly connects to the ESMO 2026 RASolute 302 data by extending that clinical package into a potential second major geography. If the European Commission follows the opinion with an approval, Revolution Medicines would be working toward two large commercial rollouts in the U.S. and Europe at once. That scenario can stress test its young commercial infrastructure and supply chain. This decision also interacts with the broader catalyst stack. Eight ongoing or planned Phase 3 trials, including the new RASolve 308 study of zoldonrasib plus pembrolizumab and chemotherapy in first line RAS G12D non squamous NSCLC, are designed around the same RAS(ON) toolkit that underpins RASONQUE. A favorable EU ruling would not answer the lung and colorectal questions, but it would show regulators are comfortable with the core mechanism in one high need setting. The operational challenge is whether Revolution Medicines can scale field teams, medical affairs and post marketing commitments while still funding that extensive late stage pipeline without putting undue strain on its balance sheet. Revolution Medicines projections point to US$3.6b in revenue and US$426.6m in earnings by 2029, from a base of no revenue and a current loss of about US$1.8b. This implies an earnings swing of roughly US$2.2b alongside a very large step up in annual sales growth over the period. Uncover why Revolution Medicines' fair value indicates a 36% potential upside to its current price that could narrow quickly. NasdaqGS:RVMD 1-Year Stock Price Chart Exploring Other Perspectives One alternate angle focuses less on RASolute 302 and more on dilution and profitability timing. The lowest analysts were penciling in US$1.8b of revenue and about US$316.1m of earnings by 2029, far below the US$3.6b and US$426.6m consensus view. That is a meaningfully more cautious Revolution Medicines story. These pre news forecasts could shift as investors reassess the ESMO subgroup data and CHMP opinion. Explore 4 other Revolution Medicines fair value estimates, including one that suggests it could be worth just $190.52. Form Your Own Verdict Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider your own analysis and judgment.  A great starting point for your Revolution Medicines research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision. See our latest analysis for Revolution Medicines. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Revolution Medicines' overall financial health at a glance.  Looking for more investment ideas beyond Revolution Medicines? If the RAS story at Revolution Medicines has your attention, it can be useful to set it alongside other opportunities and see how it compares on quality, risk and balance sheet strength. The Simply Wall St Screener can help you quickly filter the broader market down to a focused watchlist that matches your own risk tolerance and return goals.  If you prefer resilient businesses with lower perceived risk and steadier profiles across cycles, you can scan a curated set of 32 resilient stocks with low risk scores to see what else might deserve a place on your radar. If financial strength and cleaner balance sheets matter most to you, you can review a list of solid balance sheet and fundamentals (24 results) that may help you assess Revolution Medicines alongside more established operators. If you are hunting for early stage opportunities that still pass a basic quality filter, you could compare Revolution Medicines with a group of 19 high quality undiscovered gems that may not yet be widely followed.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2679228502","isCrawlerRequest":true}